1. Home
  2. RLX vs NTLA Comparison

RLX vs NTLA Comparison

Compare RLX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RLX Technology Inc. each representing the right to receive one (1) ordinary share

RLX

RLX Technology Inc. each representing the right to receive one (1) ordinary share

HOLD

Current Price

$1.69

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$11.77

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLX
NTLA
Founded
2018
2014
Country
China
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
RLX
NTLA
Price
$1.69
$11.77
Analyst Decision
Hold
Buy
Analyst Count
1
23
Target Price
$2.50
★ $20.02
AVG Volume (30 Days)
3.0M
★ 3.5M
Earning Date
05-15-2026
05-07-2026
Dividend Yield
★ 0.75%
N/A
EPS Growth
N/A
★ 27.43
EPS
★ N/A
N/A
Revenue
N/A
★ $67,671,000.00
Revenue This Year
$55.89
N/A
Revenue Next Year
$15.07
$62.75
P/E Ratio
$28.09
★ N/A
Revenue Growth
N/A
★ 16.92
52 Week Low
$1.67
$7.95
52 Week High
$2.68
$28.24

Technical Indicators

Market Signals
Indicator
RLX
NTLA
Relative Strength Index (RSI) 35.08 44.55
Support Level $1.67 $11.51
Resistance Level $2.08 $13.88
Average True Range (ATR) 0.04 0.60
MACD 0.00 -0.01
Stochastic Oscillator 25.00 33.13

Price Performance

Historical Comparison
RLX
NTLA

About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share

RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market. The company has two reportable segments, Core Markets and Europe Acquisition. The majority of the revenue is earn from Core Markets segment.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: